High-risk human papillomavirus (HR-HPV) testing is increasingly important. We therefore examined the impact on accuracy of repeated versus one-time testing, type-specific versus pooled detection, and assay analytic sensitivity. By using a nested casecontrol design from the ASCUS-LSIL Triage Study, we selected women with incident cervical intraepithelial neoplasia grade 2 or grade 3 (CIN2/3; n ‫؍‬ 325) and a random sample of women with <CIN2 as controls (n ‫؍‬ 401). HPV DNA status was assessed using hybrid capture 2 (HC2), a pooled test for 13 HR-HPV types, and the linear array (LA) and the line blot assay (LBA), two PCRbased HPV genotyping assays, at enrollment and the 6-month follow-up visit. The relative sensitivity and specificity for different permutations of multiple measurements were compared to a single measurement using marginal regression models. We found that repeat detection of any HR-HPV (by HC2, LA, or LBA) and of type-specific persistence (by LA or LBA) were significantly more specific but less sensitive than use of a single time point measurement of any HR-HPV. Sensitivity decreased and specificity increased further when testing intervals were increased from 12 to 24 months. Including detection of borderline carcinogenic/ noncarcinogenic HPV types with HR-HPV types decreased specificity for repeat measures of HPV with no impact on sensitivity. Similar patterns were observed when we used a CIN3 end point. We conclude that assay performance for detecting incident CIN2/3 was affected by which types were included, the analytic sensitivity of the assay, and the testing interval. These trade-offs need to be considered when assessing the potential overall clinical utility of repeated testing for HR-HPV DNA to identify women at risk for CIN2/3. C ervical infections by any of approximately 13 anogenital highrisk human papillomavirus (HR-HPV) types are generally recognized as the cause of cervical cancer (14, 23) . Although the recent introduction of a highly effective prophylactic HPV vaccine has great promise for the prevention of persistent infections and precancerous lesions, cervical cancer screening will still be required because the current vaccines do not protect against all carcinogenic HPV types and do not treat preexisting HPV infections and related disease.
C
ervical infections by any of approximately 13 anogenital highrisk human papillomavirus (HR-HPV) types are generally recognized as the cause of cervical cancer (14, 23) . Although the recent introduction of a highly effective prophylactic HPV vaccine has great promise for the prevention of persistent infections and precancerous lesions, cervical cancer screening will still be required because the current vaccines do not protect against all carcinogenic HPV types and do not treat preexisting HPV infections and related disease.
While anogenital HPVs are the most common sexually transmitted infections worldwide, only a small fraction of these infections lead to the development of invasive cancer and its precursor, cervical intraepithelial neoplasia 3 (CIN3) (17) . Most HR-HPV infections clear within 1 to 2 years after initial detection; however, persistent detection of HR-HPV for a year or more is a major risk factor for progression to precancer and cancer (3, 10, 21) .
HR-HPV DNA detection is more sensitive than Pap smears for detection of CIN2, CIN3, or cancer, and it has a higher negative predictive value (1, 15, 19) . HR-HPV DNA testing is currently recommended for triage of cytological diagnoses of atypical squamous cells of undetermined significance (ASCUS), as a cotest with the Pap smear in the general screening of women Ն30 years of age, and for follow-up of women after colonoscopy and treatment (25) . The high negative predictive value of HR-HPV DNA testing also allows for the safe extension of screening intervals from 1 to 3 years or more (5, 22) .
The primary limitation of HR-HPV DNA testing as a primary screening tool is the relatively low specificity due to its inability to distinguish between benign, transient HPV infections and those that will persist and possibly develop into cervical precancer. As a result, HPV testing will label more women as screen positive, which can lead to unnecessary and sometimes invasive follow-up procedures. Given the demonstrated role of viral persistence on the relative and absolute risk of CIN3 (3, 11) , there is the possibility that repeat measurements of HPV DNA over a given interval may improve the specificity of DNA detection by identifying persistent versus transient infections that predict significantly lower risk of CIN3. The goal of this analysis was to evaluate different methods/strategies for the detection of HPV persistence and their effects on identifying women with cervical precancerous lesions in the squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesions (LSIL) triage study (ALTS).
MATERIALS AND METHODS
Study design and population. The ALTS (1997 to 2001) was a multisite, randomized clinical trial that compared three management strategies (immediate colposcopy [IC] , HPV triage, and conservative management [CM]) for women referred for ASCUS (n ϭ 3,488) or LSIL (n ϭ 1,572) by conventional cytology (1, 16) . (Note that ASCUS under the 1991 Bethesda system was slightly more inclusive, particularly of probable reactive changes and ASC-H [atypical squamous cells for which a high-grade intraepithelial lesion cannot be ruled out], than the ASCUS category of the 2001 Bethesda system.) The National Cancer Institute and local institu-tional review boards approved the study, and all participants provided written, informed consent.
At enrollment and follow-up visits over the 2-year duration, all women underwent a pelvic examination with collection of two cervical specimens: the first specimen in PreservCyt for ThinPrep cytology medium (Hologic, Bedford, MA) for HPV testing by Hybrid Capture 2 (HC2; Qiagen, Gaithersburg, MD), and the second in specimen transport medium (STM; Qiagen). Women in all three arms of the study were reevaluated by cytology every 6 months during the 2 years and were sent to colposcopy if cytology showed a high-grade squamous intraepithelial lesion (HSIL). An exit examination with colposcopy was scheduled for all women, regardless of study arm or prior procedures, at the completion of the follow-up. We refer readers to other references for details on randomization, examination procedures, patient management, and laboratory and pathology methods (1, 16) .
This nested case-control study included women diagnosed with CIN2/3 by clinical center pathology or CIN3ϩ by a quality control (QC) pathology group during follow-up (defined as cases), as well as a random sample of women who did not develop CIN2/3 (defined as controls). Women were censored at the visit of CIN2ϩ diagnosis starting at the 12-month follow-up or at 24 months if they were disease free. Women diagnosed with CIN2/3 at enrollment and the 6 month follow-up were not included in this analysis. HPV DNA data generated by HC2, the linear array (LA), and the line blot assay (LBA) testing methods were utilized from all available study visits for both cases and controls that had at least 2 test results for all three testing methods. A total of 726 women met these criteria and were included in this analysis. While there were no differences in demographic factors among women with CIN2/3 included in this analysis compared to the entire ALTS cohort, women with ϽCIN2 in the current study were more likely to be Ն25 years of age (60.6% versus 52.4%; P ϭ 0.004) and have a Pap referral diagnosis of ASCUS compared to those women with ϽCIN2 not included in our analysis (29.2% versus 19.7%; P Ͻ 0.001). However, adjustment by these factors in regression models did not significantly alter the relative differences in specificity by testing modality or interval.
HPV DNA testing. HC2, a DNA test for a pool of 13 carcinogenic HPV types (HPV16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, and -68) was performed on residual PreservCyt specimens as previously described (20) . STM specimens were tested for 27 HPV types (HPV6, -11, -16, -18, -26, -31, -33, -35, -39, -40, -42, -45, -51 to -59, -66, -68, -73, and -82 to -84) (18) . In addition, a separate category of borderline carcinogenic/noncarcinogenic types was created that included HPV types 53, 66, 67, 70, 73, 82, and 82v, types untargeted but detected by HC2 as a result of cross-reactivity (4).
Pathology and treatment. Clinical management was based on the clinical center pathologists' cytological and histological diagnoses. In addition, all referral smears, ThinPrep, and histology slides were sent to the Pathology Quality Control Group (QC Pathology) based at the Johns Hopkins Hospital for independent review and diagnosis. CIN2 or worse (CIN2/3) diagnosis based on the clinical center pathology or CIN3ϩ diagnosis based on the QC pathology review triggered treatment by loop electrosurgical excision procedure (LEEP). In addition, women with persistent LSIL or carcinogenic HPV-positive ASCUS at the time of the exit from the study were offered LEEP.
Statistical analysis. A previous analysis conducted in the ALTS compared two testing strategies for detecting CIN3ϩ diagnosed in the second year of ALTS: 12-month repeat detection of HR-HPV DNA initially detected at enrollment as measured by pooled-probe HC2, compared with 12-month type-specific persistence as measured by LBA (6). We previously observed that HC2, a pooled test for 13 carcinogenic HPV genotypes, was more sensitive but less specific for CIN3ϩ than a positive LBA test for any of 13 carcinogenic HPV genotypes. We also observed that LA was more analytically sensitive than LBA, most likely the result of increased DNA input in the assay. As a consequence of the greater analytical sensitivity of LA (versus LBA), LA was similarly sensitive but less specific for CIN3 compared to HC2 (7). Lastly, 277 women (38.1%) at the enrollment visit were genotyped for 27 types of HPV using the LBA test at the enrollment visit only. These types initially tested were HR-HPV types similarly measured by linear array.
Here, we expanded on the previous studies to examine the impacts of different detection methods on the clinical performance of repeat measures of HPV DNA for identification of women with incident CIN2/3. Specifically, we considered the following parameters: (i) testing interval (baseline detection of pooled HR-HPV by HC2 or LA versus repeat detection at 12 or 24 months); (iii) repeatedly testing positive for any carcinogenic HPV type versus detection of type-specific HPV persistence; (iii) inclusion (versus not) of borderline carcinogenic HPV genotypes at baseline; (iv) 12-month versus 24-month interval; (iv) impact of analytic sensitivity (LA versus LBA).
The goal of this analysis was to estimate the sensitivity and specificity of a colposcopic referral threshold of different measures of HPV persistence for the detection of incident CIN2/3 at 12, 18, and 24 months; secondarily, we used CIN3 as our diagnostic end point, excluding CIN2 from the analysis. We compared performance estimates for repeat testing versus the detection of HR-HPV DNA at a single time point. Because of the case-control design of this analysis, changes in performance parameters by referral threshold and by HPV DNA testing methodology were Performance ratios with 95% confidence intervals are shown for comparisons between different measurements of HPV. In all cases, the differences between baseline measure and 12-month repeat measures and the 12-month and 24-month repeat measures were highly significantly different (P Ͻ 0.001). There was no statistically significant difference in performance between assays, except that LA was less specific than HC2 for the 12-month repeat performance
Performance ratio for 12-month or 24-month repeat HR-HPV versus single baseline HR-HPV measurement.
c Performance ratio for 24-month versus 12-month repeat HR-HPV measurement.
summarized using sensitivity and specificity ratios. A marginal regression model was used with a robust variance to take into account the correlation of repeated testing occurring within the same individual across time (12) . This methodology utilizes Wald's test to assess the statistical significance of the difference between performance measures and directly corresponds to McNemar's test, but it allows for simultaneous comparison across multiple groups as well as the generation of a relative measure of the difference in sensitivity and specificity. A P value of Ͻ0.05 was considered statistically significant. All analyses were performed using Stata version 11.1 (Stata, College Station, TX).
RESULTS
Overall, 325 women were diagnosed with CIN2/3 (241 with CIN3) during follow-up in this study. Women with CIN2/3 were more likely to be under 30 years of age, have a referral Pap of ASCUS (P Ͻ 0.001) rather than LSIL, be part of the conservative management study trial arm (P Ͻ 0.001), be from clinical centers 1 and 4, report former use of birth control at enrollment (P ϭ 0.05), and be a current or former smoker (P Ͻ 0.001) than controls at enrollment (Table 1) . Single versus repeat HR-HPV DNA detection. In this population, single time point detection of one or more (any) HR-HPV type by either HC2 or LA had very high (relative) sensitivity (Ͼ95%) for incidentally detected CIN2/3 or CIN3 at the 24-month exit visit (Table 2) . However, the (relative) specificity was poor (ϳ30%). Adding a second measurement of any HR-HPV at 12 months decreased sensitivity by approximately 8% (P Ͻ 0.001 for both assays) but doubled the specificity (P Ͻ 0.001 for both assays). Using a 24-month interval between HR-HPV measurements further decreased sensitivity by approximately 20% compared to the single measurement (P Ͻ 0.001 for both assays) and by 10% compared to 12-month repeat detection (P Ͻ 0.001 for both assays), but it increased specificity by an additional 20 to 30% (P Ͻ 0.001 for both assays). There were no appreciable differences in the sensitivity and specificity between HC2 and LA, with one exception: the 12-month repeat detection of HR-HPV by HC2 was more specific than LA (P Ͻ 0.001).
Type-specific versus pooled HPV DNA detection. Because LA detected individual HPV genotypes, we were able to compare detection of type-specific HR-HPV persistence versus simulated pooling of HR-HPV (by using HC2) ( Table 3) . Requiring type-specific HR-HPV persistence significantly decreased the sensitivity for both end points by approximately 5% for a 12-month interval and by more than 20% for a 24-month interval while increasing the specificity by about 10% for both intervals.
Impact of HPV genotype specificity on relative test performance. Expanding the definition of the HPV types beyond HR-HPV to include borderline carcinogenic/noncarcinogenic HPV types HPV53, -66, -67, -70, -73, -82, and -82v, the types that are often detected by HC2 (4), did not appreciably increase the sensitivity of a single baseline measurement by LA for CIN2/3 or CIN3 but reduced the specificity by 15% (P Ͻ 0.001) ( Table 4 ). For repeat measures at 12-month and 24-month intervals, the additional HPV types increased sensitivity for both end points and decreased in specificity with a similar magnitude.
Impact of HPV-type analytic sensitivity on relative test performance. We previously demonstrated the LA had a greater analytic sensitivity for most HR-HPV types because of greater DNA input in the LA assay compared to LBA (17) . For the single baseline measurement of HR-HPV, there were no significant differences in sensitivity for CIN2/3 or CIN3 between the two assays (Table 5) . For multiple measurements, the sensitivity for CIN2/3 and CIN3 was greater for LA than LBA, and there was a tendency for these differences to be greater for the 24-month interval compared to the 12-month interval. For single and multiple measures of HR-HPV, LBA was significantly more specific than LA (P ϭ 0.001 for all). 
DISCUSSION
We estimated the relative impact of different methods for detecting HPV persistence and its accuracy on identifying women at risk of CIN2/3. All the parameters we investigated influenced the sensitivity for detection of incident CIN2/3 or CIN3 with a concomitant trade-off in specificity, creating a receiver operator characteristic-like curve, as illustrated in Fig. 1 . Single versus repeat HR-HPV DNA detection. The biggest impact on performance was observed when we compared single baseline measurement to repeat measures of HR-HPV. Repeat detection of any HR-HPV or type-specific HR-HPV across either a 12-or 24-month interval increased specificity 2-fold but decreased sensitivity by Յ20% for detection of CIN2/3 or CIN3 compared with a single positive HR-HPV DNA test. Since most women will not have disease, the gains in specificity may have a much more profound impact on the general population undergoing routine screening. Increasing the testing interval from 12 to 24 months resulted in a further decline of sensitivity, suggesting that a fraction of the CIN2/3 identified was not preceded by long-term persistent HR-HPV detection and was caused by incident HPV infections acquired after enrollment. An increasing specificity from the single baseline measure, to repeat measures at a 12-month interval, to repeat measures at 24 months reinforces the notion that a majority of HR-HPV infections clear within 1 to 2 years (9).
Type-specific versus pooled HPV DNA detection. The requirement for HPV type-specific persistence to define women who are persistently HR-HPV positive only slightly decreased sensitivity and increased specificity, suggesting that pooling of HPV genotypes is a very good proxy for measuring type-specific persistence, as previously noted (6) . Furthermore, the changes in performance due to measurement of type-specific persistence suggest that some CIN2/3 lesions develop relatively rapidly after acquisition of the causal infection. College-aged women with incident HPV16 and -18 infections demonstrated a relatively elevated rate of incident CIN 2/3 within the first 36 months after infection (24) . These rapidly developing lesions and their causal type-specific HPV infection exist, particularly in younger women, within the context of other multiple noncausal, yet oncogenic, HPV types. Thus, multiple, concurrent noncausal types may on the whole be more readily detected than the single causal type, leading to more false negatives at the type-specific level and thereby decreasing the sensitivity. Pooled detection of multiple oncogenic HPV genotypes can help minimize these errors, because the test is positive whether or not due to the causal HPV type but will result in decreases in specificity, potentially leading to an increased frequency of unnecessary follow-up screening.
Impact of non-HR-HPV cross-reactive types on relative test performance. Including the non-HR-HPV types that HC2 is most likely to detect through cross-reactivity in the definition of HPV positivity increased sensitivity for repeat measures, perhaps through the same phenomena described above, i.e., more liberal definitions of HPV positivity avoid some of the uncommon errors in failing to detect a specific type(s). The cost again was a loss in specificity.
Impact of HPV-type analytic sensitivity on relative test performance. The use of the more analytically sensitive LA for measurement of repeat positivity and type-specific persistence at 12 and 24 months proved to be more clinically sensitive but less specific for detection of CIN2/3 than its predecessor, LBA. Differences in performance between LA and LBA were most likely due to the 2-fold difference in the amount of input DNA utilized in the PCR, as previously discussed (2) . The optimization of the linear array protocol for commercial use, such as incorporation of ␤-globin controls and the use of premixed PCR and reverse hybridization reagents, as well as the differences in DNA extraction methodologies used for each assay (LBA uses a manual centrifugation-based method involving proteinase K digestion followed by ethanol precipitation, whereas LA uses a robotic, nucleic acid-based purification method) may have contributed to the differences in performance between the two assays. Lastly, the lower sensitivity observed when using the LBA may also be a result of limited genotyping information collected at enrollment for approximately 40% of the women in this study due to initial use of a limited primer set. Sensitivity analyses that restricted the study sample to women with complete genotyping information from both the LA and LBA showed no significant change in the sensitivity or specificity across all measurement metrics (data not shown). This was to be expected, given that the types measured by LBA initially using this limited primer set included all high-risk HPV types measured by LA.
Study limitations. The use of a nested case-control study that overselected women with CIN2/3 as cases increased the prevalence of disease and thus excluded the ability to accurately estimate predictive values or absolute risks that can be generalized to a larger population. Furthermore, the ALTS from which the current analysis was conducted recruited women primarily Ͻ30 years of age with mild to low-grade cervical abnormalities. Therefore, the age among women with CIN 2/3 in this case-control study was younger than what is typically observed in the general population of women undergoing routine screening (17) . As a result of these limitations, this study focused on sensitivity and specificity as primary measures of performance. In addition, the case-control study was nested within a triage population of women who were enrolled based on referral from an ASCUS or LSIL cytological screening result and therefore were likely to have HPV infections with higher HPV viral loads. The impact of differences in analytic sensitivity on clinical sensitivity might be less pronounced in a population whose HPV viral loads are much above the thresholds of detection. Therefore, the generalizabilities of the sensitivity and specificity estimates for single and repeat HPV DNA detection to the general screening population are limited. These measure- Population-based prospective studies that perform multiple HPV DNA measurements across set screening intervals are needed to provide more unbiased estimates of these performance parameters. Summary. This study, one of the first to systematically evaluate the potential benefit of repeat HPV DNA testing compared to single testing across a number of different HPV DNA testing methods, found that repeat detection of HR-HPV DNA conferred a significantly higher specificity with concomitantly small reductions in sensitivity than did a single HR-HPV test, particularly in women 30 years old and younger (6, 8) . Differences in performance varied little between testing methodology, suggesting that the modest analytic performance differences between currently validated HPV DNA assays have minimal impacts on the clinical performance. We did note that the more liberal the definition of a positive result (e.g., more types, fewer measurements, not requiring type-specific persistence, and greater analytic sensitivity), led to greater sensitivity for CIN2/3 but at a performance cost of lower specificity. In conclusion, the significant benefit observed in this study of enhanced specificity for ruling out women without disease needs to be evaluated in additional studies against the declines in sensitivity, in order to more clearly define the balance between benefit from the high sensitivity and harms due to potential overtreatment when using HR-HPV DNA testing.
